GF SEC (01776) will publicly issue corporate bonds (first tranche) for professional investors, listed on the Shenzhen Stock Exchange in 2026.

18:14 11/03/2026

Guangfa Securities (01776) has announced that in accordance with the relevant regulations of the Shenzhen Stock Exchange for the listing of bonds, Guangfa Securities Co., Ltd. will publicly issue corporate bonds (first tranche, Series 1) and corporate bonds (first tranche, Series 2) for professional investors in 2026. These bonds meet the conditions for listing on the Shenzhen Stock Exchange and will be listed starting from March 12, 2026. They will be traded by professional institutional investors through various trading methods including matched trading, click trading, inquiry trading, bidding trading, and negotiated trading. The bonds are abbreviated as 26 Guangfa 02, with a total issuance amount of 2.85 billion RMB, a maturity period of 3 years, and an annual coupon rate of 1.80%.

GF SEC (01776) announced that, in accordance with the relevant regulations of the Shenzhen Stock Exchange for bond listing, GF SEC Limited will publicly issue corporate bonds (first tranche) targeted at professional investors in 2026 (class one) and corporate bonds (first tranche) targeted at professional investors in 2026 (class two). The bonds meet the conditions for listing on the Shenzhen Stock Exchange and will be listed on March 12, 2026 for trading by professional institutional investors. Trading methods include matched trading, click trading, inquiry trading, bidding trading, and negotiated trading. The bond abbreviation is 26GF02, with a total issuance amount of 2.85 billion yuan, a term of 3 years, and a annual coupon rate of 1.80%.

Power Construction Corporation of China, Ltd (POWERCHINA) has signed a joint venture contract for a 56.36 billion yuan highway design and construction general contracting project.

East China Pharmaceuticals (000963.SZ): The clinical trial application for injectable drug HDM2024 has been approved by the US FDA.

SHOUHUI GROUP (02621) expects a net profit of approximately 780 million to 800 million yuan in 2025.

Power Construction Corporation of China, Ltd (POWERCHINA) has signed a joint venture contract for a 56.36 billion yuan highway design and construction general contracting project.

East China Pharmaceuticals (000963.SZ): The clinical trial application for injectable drug HDM2024 has been approved by the US FDA.

SHOUHUI GROUP (02621) expects a net profit of approximately 780 million to 800 million yuan in 2025.